BMJ  2005;330 (16 April), doi:10.1136/bmj.330.7496.0-a

Quetiapine and rivastigmine may not work for dementia

An atypical antipsychotic, quetiapine, and a central cholinesterase inhibitor, rivastigmine, may not be effective for treating agitation in people with dementia in institutional care. In a randomised double blind placebo controlled trial including 93 patients with Alzheimer's disease, Ballard and colleagues (p 874) found that both of these drugs failed to reduce agitation or ameliorate the decline of cognition after six weeks and after 26 weeks of follow-up. In these patients, quetiapine was associated with accelerated cognitive decline.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Article

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

Clive Ballard, Marisa Margallo-Lana, Edmund Juszczak, Simon Douglas, Alan Swann, Alan Thomas, John O'Brien, Anna Everratt, Stuart Sadler, Clare Maddison, Lesley Lee, Carol Bannister, Ruth Elvish, and Robin Jacoby
BMJ 2005 330: 874. [Abstract] [Full Text] [PDF]

Online poll

Find out more >>